Open-angle glaucoma - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Open-angle glaucoma - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Open-angle glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Open-angle glaucoma: Overview
Glaucoma is an eye disease that gradually steals vision. Open-angle glaucoma is the most common type of glaucoma. Open-angle glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. Glaucoma affects 70 million people worldwide and is the second leading cause of blindness. The underlying pathology of Open-angle glaucoma lies in the apoptosis of retinal ganglion cells. Open-angle glaucoma can be clinically evaluated using a variety of diagnostic tools including optic disc changes, visual field changes, and elevated intraocular pressure. The goal of treatment of open-angle glaucoma is to prevent the progression of optic nerve head changes and also the prevention of deterioration of visual field.
'Open-angle glaucoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Open-angle glaucoma pipeline landscape is provided which includes the disease overview and Open-angle glaucoma treatment guidelines. The assessment part of the report embraces, in depth Open-angle glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Open-angle glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Open-angle glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Open-angle glaucoma Emerging Drugs
Further product details are provided in the report
Open-angle glaucoma: Therapeutic Assessment
This segment of the report provides insights about the different Open-angle glaucoma drugs segregated based on following parameters that define the scope of the report, such as:
Open-angle glaucoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Open-angle glaucoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Open-angle glaucoma drugs.
Open-angle glaucoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Open-angle glaucoma - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Open-angle glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Open-angle glaucoma: Overview
Glaucoma is an eye disease that gradually steals vision. Open-angle glaucoma is the most common type of glaucoma. Open-angle glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. Glaucoma affects 70 million people worldwide and is the second leading cause of blindness. The underlying pathology of Open-angle glaucoma lies in the apoptosis of retinal ganglion cells. Open-angle glaucoma can be clinically evaluated using a variety of diagnostic tools including optic disc changes, visual field changes, and elevated intraocular pressure. The goal of treatment of open-angle glaucoma is to prevent the progression of optic nerve head changes and also the prevention of deterioration of visual field.
'Open-angle glaucoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Open-angle glaucoma pipeline landscape is provided which includes the disease overview and Open-angle glaucoma treatment guidelines. The assessment part of the report embraces, in depth Open-angle glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Open-angle glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Open-angle glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Open-angle glaucoma.
This segment of the Open-angle glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Open-angle glaucoma Emerging Drugs
- QLS-101: Qlaris Bio
- Razuprotafib: Aerpio Pharmaceuticals
Further product details are provided in the report
Open-angle glaucoma: Therapeutic Assessment
This segment of the report provides insights about the different Open-angle glaucoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Open-angle glaucoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Open-angle glaucoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Open-angle glaucoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Open-angle glaucoma drugs.
Open-angle glaucoma Report Insights
- Open-angle glaucoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Open-angle glaucoma drugs?
- How many Open-angle glaucoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Open-angle glaucoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Open-angle glaucoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Open-angle glaucoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Qlaris Bio
- Ocular Therapeutix
- SALVAT
- Aerpio Pharmaceuticals
- Ocularis Pharma
- PolyActiva
- AbbVie
- Annexon
- Skye Bioscience
- GrayBug
- Quark Pharmaceuticals
- QLS-101
- Travoprost ophthalmic
- SVT18412
- Razuprotafib
- Phentolamine
- PA5108
- AGN 193408 sustained-release
- ANX 007
- NB 1111
- GB 401
- QPI-1017
Introduction
Executive Summary
Open-angle glaucoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Open-angle glaucoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Open-angle glaucoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Open-angle glaucoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Travoprost ophthalmic: Ocular Therapeutix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
QLS-101: Qlaris Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
PA5108: PolyActiva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
NB 1111: Skye Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Open-angle glaucoma Key Companies
Open-angle glaucoma Key Products
Open-angle glaucoma- Unmet Needs
Open-angle glaucoma- Market Drivers and Barriers
Open-angle glaucoma- Future Perspectives and Conclusion
Open-angle glaucoma Analyst Views
Open-angle glaucoma Key Companies
Appendix
Executive Summary
Open-angle glaucoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Open-angle glaucoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Open-angle glaucoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Open-angle glaucoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Travoprost ophthalmic: Ocular Therapeutix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
QLS-101: Qlaris Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
PA5108: PolyActiva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
NB 1111: Skye Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Open-angle glaucoma Key Companies
Open-angle glaucoma Key Products
Open-angle glaucoma- Unmet Needs
Open-angle glaucoma- Market Drivers and Barriers
Open-angle glaucoma- Future Perspectives and Conclusion
Open-angle glaucoma Analyst Views
Open-angle glaucoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Open-angle glaucoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Open-angle glaucoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Open-angle glaucoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Open-angle glaucoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
